{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T20:13:51Z","timestamp":1770149631044,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T00:00:00Z","timestamp":1481760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T00:00:00Z","timestamp":1481760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ovarian cancer (OC) is the second leading cause of gynecological cancer death worldwide. Although the list of biomarkers is still growing, molecular mechanisms involved in OC development and progression remain elusive. We recently demonstrated that lower expression of the molecular chaperone TRAP1 in OC patients correlates with higher tumor grade and stage, and platinum resistance. Herein we show that TRAP1 is often deleted in high-grade serous OC patients (<jats:italic>N<\/jats:italic>=579), and that TRAP1 expression is correlated with the copy number, suggesting this could be one of the driving mechanisms for the loss of TRAP1 expression in OC. At molecular level, downregulation of TRAP1 associates with higher expression of p70S6K, a kinase frequently active in OC with emerging roles in cell migration and tumor metastasis. Indeed, TRAP1 silencing in different OC cells induces upregulation of p70S6K expression and activity, enhancement of cell motility and epithelial\u2013mesenchymal transition (EMT). Consistently, in a large cohort of OC patients, TRAP1 expression is reduced in tumor metastases and directly correlates with the epithelial marker E-Cadherin, whereas it inversely correlates with the transcription factor Slug and the matrix metallopeptidases 2 and 9. Strikingly, pharmacological inhibition of p70S6K reverts the high motility phenotype of TRAP1 knock-down cells. However, although p70S6K inhibition or silencing reduces the expression of the transcription factors Snail and Slug, thus inducing upregulation of E-Cadherin expression, it is unable to revert EMT induced by TRAP1 silencing; furthermore, p70S6K did not show any significant correlation with EMT genes in patients, nor with overall survival or tumor stage, suggesting an independent and predominant role for TRAP1 in OC progression. Altogether, these results may provide novel approaches in OC with reduced TRAP1 expression, which could be resistant to therapeutic strategies based on the inhibition of the p70S6K pathway, with potential future intervention in OC invasion and metastasis.<\/jats:p>","DOI":"10.1038\/cddis.2016.400","type":"journal-article","created":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T14:19:51Z","timestamp":1481811591000},"page":"e2522-e2522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial\u2013mesenchymal transition"],"prefix":"10.1038","volume":"7","author":[{"given":"Maria R","family":"Amoroso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo S","family":"Matassa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilenia","family":"Agliarulo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Avolio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haonan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenza","family":"Sisinni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Lettini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani","family":"Gabra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Landriscina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franca","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,15]]},"reference":[{"key":"BFcddis2016400_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ . Cancer statistics 2009 CA Cancer J Clin 2009; 59: 225\u2013249.","journal-title":"CA Cancer J Clin"},{"key":"BFcddis2016400_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1200\/JCO.2003.02.553","volume":"21","author":"MA Bookman","year":"2003","unstructured":"Bookman MA . Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 2003; 21: 149\u2013167.","journal-title":"J Clin Oncol"},{"key":"BFcddis2016400_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S1470-2045(02)00846-X","volume":"3","author":"M Harries","year":"2002","unstructured":"Harries M, Gore M . Chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol 2002; 3: 529\u2013536.","journal-title":"Lancet Oncol"},{"key":"BFcddis2016400_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","volume":"92","author":"MJ Piccart","year":"2000","unstructured":"Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699\u2013708.","journal-title":"J Natl Cancer Inst"},{"key":"BFcddis2016400_CR5","doi-asserted-by":"publisher","first-page":"8213","DOI":"10.3390\/ijms14048213","volume":"14","author":"ZC Dobbin","year":"2013","unstructured":"Dobbin ZC, Landen CN . The importance of the PI3K\/AKT\/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci 2013; 14: 8213\u20138227.","journal-title":"Int J Mol Sci"},{"key":"BFcddis2016400_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/5042","volume":"21","author":"L Shayesteh","year":"1999","unstructured":"Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21: 99\u2013102.","journal-title":"Nat Genet"},{"key":"BFcddis2016400_CR7","doi-asserted-by":"publisher","first-page":"5853","DOI":"10.1038\/sj.onc.1207721","volume":"23","author":"DA Altomare","year":"2004","unstructured":"Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004; 23: 5853\u20135857.","journal-title":"Oncogene"},{"key":"BFcddis2016400_CR8","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1002\/cncr.22195","volume":"107","author":"J Castellvi","year":"2006","unstructured":"Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006; 107: 1801\u20131811.","journal-title":"Cancer"},{"key":"BFcddis2016400_CR9","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1210\/en.2005-1404","volume":"147","author":"HY Zhou","year":"2006","unstructured":"Zhou HY, Wong AS . Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology 2006; 147: 2557\u20132566.","journal-title":"Endocrinology"},{"key":"BFcddis2016400_CR10","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/sj.onc.1204253","volume":"20","author":"AS Wong","year":"2001","unstructured":"Wong AS, Pelech SL, Woo MM, Yim G, Rosen B, Ehlen T et al. Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis? Oncogene 2001; 20: 1318\u20131328.","journal-title":"Oncogene"},{"key":"BFcddis2016400_CR11","doi-asserted-by":"publisher","first-page":"6524","DOI":"10.1158\/0008-5472.CAN-07-6302","volume":"68","author":"YL Pon","year":"2008","unstructured":"Pon YL, Zhou HY, Cheung AN, Ngan HY, Wong AS . p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells. Cancer Res 2008; 68: 6524\u20136532.","journal-title":"Cancer Res"},{"key":"BFcddis2016400_CR12","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.2741\/3433","volume":"14","author":"CC Alves","year":"2009","unstructured":"Alves CC, Carneiro F, Hoefler H, Becker KF . Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. Front Biosci 2009; 14: 3035\u20133050.","journal-title":"Front Biosci"},{"key":"BFcddis2016400_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4161\/cam.3.3.8259","volume":"3","author":"M Haraguchi","year":"2009","unstructured":"Haraguchi M . The role of the transcriptional regulator snail in cell detachment, reattachment and migration. Cell Adh Migr 2009; 3: 259\u2013263.","journal-title":"Cell Adh Migr"},{"key":"BFcddis2016400_CR14","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1038\/onc.2010.615","volume":"30","author":"CK Ip","year":"2011","unstructured":"Ip CK, Cheung AN, Ngan HY, Wong AS . p70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells. Oncogene 2011; 30: 2420\u20132432.","journal-title":"Oncogene"},{"key":"BFcddis2016400_CR15","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.molonc.2014.06.003","volume":"8","author":"DS Matassa","year":"2014","unstructured":"Matassa DS, Agliarulo I, Amoroso MR, Maddalena F, Sepe L, Ferrari MC et al. TRAP1-dependent regulation of p70S6K is involved in the attenuation of protein synthesis and cell migration: relevance in human colorectal tumors. Mol Oncol 2014; 8: 1482\u20131494.","journal-title":"Mol Oncol"},{"issue":"10 Pt A","key":"BFcddis2016400_CR16","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1016\/j.bbamcr.2015.05.034","volume":"1853","author":"I Agliarulo","year":"2015","unstructured":"Agliarulo I, Matassa DS, Amoroso MR, Maddalena F, Sisinni L, Sepe L et al. TRAP1 controls cell migration of cancer cells in metabolic stress conditions: correlations with AKT\/p70S6K pathways. Biochim Biophys Acta 2015; 1853 (10 Pt A): 2570\u20132579.","journal-title":"Biochim Biophys Acta"},{"key":"BFcddis2016400_CR17","first-page":"235","volume":"2","author":"DS Matassa","year":"2012","unstructured":"Matassa DS, Amoroso MR, Maddalena F, Landriscina M, Esposito F . New insights into TRAP1 pathway. Am J Cancer Res 2012; 2: 235\u2013248.","journal-title":"Am J Cancer Res"},{"key":"BFcddis2016400_CR18","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3892\/ijo.2014.2530","volume":"45","author":"MR Amoroso","year":"2014","unstructured":"Amoroso MR, Matassa DS, Sisinni L, Lettini G, Landriscina M, Esposito F . TRAP1 revisited: novel localizations and functions of a 'next-generation' biomarker (review). Int J Oncol 2014; 45: 969\u2013977.","journal-title":"Int J Oncol"},{"key":"BFcddis2016400_CR19","doi-asserted-by":"publisher","first-page":"5965","DOI":"10.3748\/wjg.v18.i41.5965","volume":"18","author":"JY Gao","year":"2012","unstructured":"Gao JY, Song BR, Peng JJ, Lu YM . Correlation between mitochondrial TRAP-1 expression and lymph node metastasis in colorectal cancer. World J Gastroenterol 2012; 18: 5965\u20135971.","journal-title":"World J Gastroenterol"},{"key":"BFcddis2016400_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4143\/crt.2014.46.1.55","volume":"46","author":"JJ Han","year":"2014","unstructured":"Han JJ, Baek SK, Lee JJ, Kim GY, Kim SY, Lee SH . Combination of TRAP1 and ERCC1 expression predicts clinical outcomes in metastatic colorectal cancer treated with oxaliplatin\/5-fluorouracil. Cancer Res Treat 2014; 46: 55\u201364.","journal-title":"Cancer Res Treat"},{"key":"BFcddis2016400_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1476-4598-11-69","volume":"11","author":"S Aust","year":"2012","unstructured":"Aust S, Bachmayr-Heyda A, Pateisky P, Tong D, Darb-Esfahani S, Denkert C et al. Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium. Mol Cancer 2012; 11: 69.","journal-title":"Mol Cancer"},{"key":"BFcddis2016400_CR22","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/cdd.2016.39","volume":"23","author":"DS Matassa","year":"2016","unstructured":"Matassa DS, Amoroso MR, Lu H, Avolio R, Arzeni D, Procaccini C et al. Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer. Cell Death Differ 2016 2016; 23: 1542\u20131554.","journal-title":"Cell Death Differ"},{"key":"BFcddis2016400_CR23","doi-asserted-by":"publisher","first-page":"e851","DOI":"10.1038\/cddis.2013.379","volume":"4","author":"DS Matassa","year":"2013","unstructured":"Matassa DS, Amoroso MR, Agliarulo I, Maddalena F, Sisinni L, Paladino S et al. Translational control in the stress adaptive response of cancer cells: a novel role for the heat shock protein TRAP1. Cell Death Dis 2013; 4: e851.","journal-title":"Cell Death Dis"},{"key":"BFcddis2016400_CR24","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198\u20135208.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2016400_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1042\/BJ20101024","volume":"431","author":"LR Pearce","year":"2010","unstructured":"Pearce LR, Alton GR, Richter DT, Kath JC, Lingardo L, Chapman J et al. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J 2010; 431: 245\u2013255.","journal-title":"Biochem J"},{"key":"BFcddis2016400_CR26","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1172\/JCI67841","volume":"123","author":"MC Caino","year":"2013","unstructured":"Caino MC, Chae YC, Vaira V, Ferrero S, Nosotti M, Martin NM et al. Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. J Clin Invest 2013; 123: 2907\u20132920.","journal-title":"J Clin Invest"},{"key":"BFcddis2016400_CR27","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1073\/pnas.1220659110","volume":"110","author":"S Yoshida","year":"2013","unstructured":"Yoshida S, Tsutsumi S, Muhlebach G, Sourbier C, Lee MJ, Lee S et al. Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis. Proc Natl Acad Sci USA 2013; 110: 1604\u20131612.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis2016400_CR28","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/JCI39104","volume":"119","author":"R Kalluri","year":"2009","unstructured":"Kalluri R, Weinberg RA . The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420\u20131428.","journal-title":"J Clin Invest"},{"key":"BFcddis2016400_CR29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R . Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15: 178\u2013196.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFcddis2016400_CR30","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrc3144","volume":"11","author":"S Vaughan","year":"2011","unstructured":"Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011; 11: 719\u2013725.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2016400_CR31","first-page":"6674","volume":"62","author":"JM Cuezva","year":"2002","unstructured":"Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, Santamar\u00eda G, Kim H et al. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 2002; 62: 6674\u20136681.","journal-title":"Cancer Res"},{"key":"BFcddis2016400_CR32","doi-asserted-by":"publisher","first-page":"4 305","DOI":"10.18632\/oncotarget.2010","volume":"5","author":"A Past\u00f2","year":"2014","unstructured":"Past\u00f2 A, Bellio C, Pilotto G, Ciminale V, Silic-Benussi M, Guzzo G et al. Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation. Oncotarget 2014; 5: 4 305\u20134319.","journal-title":"Oncotarget"},{"key":"BFcddis2016400_CR33","doi-asserted-by":"publisher","first-page":"6693","DOI":"10.1158\/0008-5472.CAN-14-1331","volume":"74","author":"V Condelli","year":"2014","unstructured":"Condelli V, Piscazzi A, Sisinni L, Matassa DS, Maddalena F, Lettini G et al. TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression: a novel target for BRAF-mutated colorectal tumors. Cancer Res 2014; 74: 6693\u20136704.","journal-title":"Cancer Res"},{"key":"BFcddis2016400_CR34","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/cdd.2011.128","volume":"19","author":"MR Amoroso","year":"2012","unstructured":"Amoroso MR, Matassa DS, Laudiero G, Egorova AV, Polishchuk RS, Maddalena F et al. TRAP1 and the proteasome regulatory particle TBP7\/Rpt3 interact in the endoplasmic reticulum and control cellular ubiquitination of specific mitochondrial proteins. Cell Death Differ 2012; 19: 592\u2013604.","journal-title":"Cell Death Differ"},{"key":"BFcddis2016400_CR35","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.molonc.2013.04.009","volume":"7","author":"F Maddalena","year":"2013","unstructured":"Maddalena F, Sisinni L, Lettini G, Condelli V, Matassa DS, Piscazzi A et al. Resistance to paclitxel in breast carcinoma cells requires a quality control of mitochondrial antiapoptotic proteins by TRAP1. Mol Oncol 2013; 7: 895\u2013906.","journal-title":"Mol Oncol"},{"key":"BFcddis2016400_CR36","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.cmet.2013.04.019","volume":"17","author":"M Sciacovelli","year":"2013","unstructured":"Sciacovelli M, Guzzo G, Morello V, Frezza C, Zheng L, Nannini N et al. The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase. Cell Metab 2013; 17: 988\u2013999.","journal-title":"Cell Metab"},{"key":"BFcddis2016400_CR37","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.canlet.2010.04.017","volume":"296","author":"D Liu","year":"2010","unstructured":"Liu D, Hu J, Agorreta J, Cesario A, Zhang Y, Harris AL et al. Tumor necrosis factor receptor-associated protein 1(TRAP1) regulates genes involved in cell cycle and metastases. Cancer Lett 2010; 296: 194\u2013205.","journal-title":"Cancer Lett"},{"key":"BFcddis2016400_CR38","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.cellsig.2006.05.019","volume":"18","author":"Q Meng","year":"2006","unstructured":"Meng Q, Xia C, Fang J, Rojanasakul Y, Jiang BH . Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal 2006; 18: 2262\u20132271.","journal-title":"Cell Signal"},{"key":"BFcddis2016400_CR39","doi-asserted-by":"publisher","first-page":"9133","DOI":"10.18632\/oncotarget.2362","volume":"5","author":"CK Ip","year":"2014","unstructured":"Ip CK, Yung S, Chan TM, Tsao SW, Wong AS . p70 S6 kinase drives ovarian cancer metastasis through multicellular spheroid-peritoneum interaction and P-cadherin\/b1 integrin signaling activation. Oncotarget 2014; 5: 9133\u20139149.","journal-title":"Oncotarget"},{"key":"BFcddis2016400_CR40","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nature15748","volume":"527","author":"KR Fischer","year":"2015","unstructured":"Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015; 527: 472\u2013476.","journal-title":"Nature"},{"key":"BFcddis2016400_CR41","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature16064","volume":"527","author":"X Zheng","year":"2015","unstructured":"Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015; 527: 525\u2013530.","journal-title":"Nature"},{"key":"BFcddis2016400_CR42","first-page":"6166","volume":"48","author":"SP Langdon","year":"1988","unstructured":"Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP et al. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 1988; 48: 6166\u20136172.","journal-title":"Cancer Res"},{"key":"BFcddis2016400_CR43","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW . NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012; 9: 671\u2013675.","journal-title":"Nat Methods"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cddis2016400.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2016400","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2016400.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T09:09:33Z","timestamp":1672823373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2016400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,15]]},"references-count":43,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12]]}},"alternative-id":["BFcddis2016400"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2016.400","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,15]]},"assertion":[{"value":"1 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}